SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

523

Regeneron Pharmaceuticals

REGN

Looking for leads, investment insights, or competitive intelligence?

CEO

Leonard S. Schleifer

CEO Title

President, Chief Executive Officer & Director

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Tarrytown, NY

Years on Fortune 500 List

-

Employees

5,400

Profile provided by S&P Global.
Regeneron Pharmaceuticals is also featured in these fortune lists
Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$4,86018.4%
Profits ($M)$895.540.8%
Assets ($M)$6,974
Total Stockholder Equity ($M)$4,449.2
Market Value — as of March 31, 2017 ($M)$41,107
Profit Ratios
Profit as % of Revenues18.4%
Profits as % of Assets12.8%
Profits as % of Stockholder Equity20.1%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)7.70
EPS % Change (from 2015)39.5%
EPS % Change (5 year annual rate)-
EPS % Change (10 year annual rate)-
Total Return
Total Return to Investors (2016)-32.4%
Total Return to Investors (5 year, annualized)46.0%
Total Return to Investors (10 year, annualized)33.7%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Regeneron Pharmaceuticals

Could a Vaccine Prevent High Cholesterol and Heart Disease?

Scientists are ready to move an experimental treatment into phase 1 trials.

Read More →
Trump's Proposed Science Cuts Could Devastate Future Generations, Pharma Expert Says

“We should only be working on two things, health and the freaking environment.”

Read More →
Pharma Executives Aren't Excited About Trump's Plans to Ease FDA Regulation

They say a robust review process is needed to convince doctors and insurers new drugs have value.

Read More →